5-Amino-1MQ
Peptide-Adjacent
CAS
42464-96-0
Molecular Weight
207
Da
Animal / In Vitro
A small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) being researched for fat loss and metabolic optimization. Preclinical data shows fat cell shrinkage and reduced adiposity without changes in food intake. No completed human trials. Research compound only.
Oral · Powder
Intranasal Suitable
No
Research Compound
Community Signal
Community signal is thin and quality-variable. 5-Amino-1MQ occupies a similar early-adopter position to SLU-PP-332, with limited personal experience reports and discussion that often conflates different compounds in the NNMT inhibitor class. Fat loss and metabolic support are the primary framing in community discussion, driven by the mechanism rather than accumulated outcome data. r/Peptides threads exist but are short. Sourcing reliability concerns are prominent given the compound's niche status and limited commercial history. The community interested in 5-Amino-1MQ tends to be highly research-literate and approaches the compound with experimental framing rather than established protocol confidence.
We break down one compound like this every week
The Honest Dose — free, no sponsorships, no agenda. Just the evidence.
What It Is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme expressed in adipose tissue and liver that plays a central role in regulating energy balance and fat metabolism. It is not a traditional peptide but falls within the peptide-adjacent class alongside SLU-PP-332 and Turkesterone. NNMT catalyzes the methylation of nicotinamide, consuming S-adenosylmethionine (SAM) in the process. Overexpression of NNMT is associated with obesity and metabolic dysfunction. By inhibiting NNMT, 5-Amino-1MQ aims to preserve NAD+ and SAM availability, shifting the cellular environment toward more efficient energy metabolism and reduced fat storage.
Mechanism of Action
NNMT consumes SAM, the primary methyl donor in cellular metabolism, to methylate nicotinamide. When NNMT is overactive, SAM depletion reduces sirtuin activity (which requires NAD+) and impairs epigenetic regulation of fat cell programming. 5-Amino-1MQ inhibits NNMT with selectivity at 10–30µM concentrations, leaving other methyltransferases largely unaffected. This preserves both NAD+ and SAM pools, supporting mitochondrial function and potentially suppressing the transcriptional program that commits progenitor cells to adipocyte differentiation. In adipocyte cell cultures, treated cells store less lipid. In rodent models, subcutaneous administration produces measurable fat loss without appetite suppression.
Use Cases
All established use cases are preclinical. In high-fat diet C57BL/6 mouse models, 5-Amino-1MQ (20mg/kg, three times daily, 11 days subcutaneous) produced progressive body weight reduction, shrinkage of white adipose tissue depots, and reduced visceral fat, with normal food intake and clean liver and kidney markers. Fat cell size reduction of 30–40% has been reported in treated versus control animals. A study published in Cell Chemical Biology documented significant reductions in body weight gain, adipose tissue expansion, and circulating triglycerides in NNMT inhibitor-treated animals on high-fat diet. No human trials completed as of 2026.
Known Risks
No human safety data. Preclinical studies report clean liver and kidney markers at research doses. The interaction between NNMT inhibition and broader SAM-dependent methylation pathways including polyamine synthesis and epigenetic regulation is not fully characterized. Long-term safety profile in humans unknown. Research compound only.
Available Forms
Available from research chemical suppliers in oral capsule or lyophilized powder form. No legitimate compounding or clinical access pathway exists in the US. Not on the FDA 503A bulk drug substances list.
Regulatory Status
Not approved by the FDA for human use. No IND filing or active human clinical trial pipeline publicly registered as of 2026. Human clinical trial activity described as "emerging but not yet mature" by independent clinical reviewers as of early 2026. Research use only.
Sources
https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/
https://pubmed.ncbi.nlm.nih.gov/35013352/
https://pubmed.ncbi.nlm.nih.gov/34304009/
Similar Compounds
SLU-PP-332, Turkesterone, AOD-9604
Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.
Join The Honest Dose →